当前位置：
X-MOL 学术
›
J. Neurol. Sci.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Guillain Barré Syndrome and its variants as a manifestation of COVID-19: A systemic review of case report and case series
Journal of the Neurological Sciences ( IF 4.4 ) Pub Date : 2021-01-01 , DOI: 10.1016/j.jns.2020.117263 Shitiz Sriwastava , Saurabh Kataria , Medha Tandon , Jenil Patel , Riddhi Patel , Abbas Jowkar , Maha Daimee , Evanthia Bernitsas , Preeti Jaiswal , Robert P. Lisak
Journal of the Neurological Sciences ( IF 4.4 ) Pub Date : 2021-01-01 , DOI: 10.1016/j.jns.2020.117263 Shitiz Sriwastava , Saurabh Kataria , Medha Tandon , Jenil Patel , Riddhi Patel , Abbas Jowkar , Maha Daimee , Evanthia Bernitsas , Preeti Jaiswal , Robert P. Lisak
Background The COVID-19 pandemic caused by SARS-COV-2 began in Wuhan, China in December 2019. Reports of COVID-19 with central (CNS) and peripheral nervous (PNS) system manifestations are emerging. In this systematic review, we compared and summarized the demographics, clinical features, Brighton criteria, immunological and laboratory findings with a focus on modified Erasmus GBS Outcome Score (mEGOS) in SARS-CoV-2 patients with GBS and its variants. Methods Based on PRISMA guidelines, we searched three databases (PubMed, Scopus, and Google Scholar) for studies on COVID-19 and GBS between December 1, 2019 to July 15, 2020. For descriptive analysis, we studied two groups with: 1) acute inflammatory demyelinating polyradiculoneuropathy (AIDP) variant, and 2) Non-AIDP/Other variants. We compared mEGOS scores for patients in both groups along with other key clinical features. Results Of the 50 GBS cases identified from 37 studies, 33 (66%) had acute inflammatory demyelinating polyradiculopolyneuropathy (AIDP) while 17 (34%) were of other (non-AIDP) variants. There mEGOS scores did not differ between AIDP patients and AMAN/AMSAN patients. Majority of the AIDP (66.7%) and AMAN/AMSAN (57.2%) patients belonged to Brighton level 1 indicating maximum diagnostic certainty. Conclusion To our knowledge, this is among the first reviews that includes GBS variants and the clinical prediction tool mEGOS for prognostication in COVID-19 patients. Further research is needed to assess whether IVIG is preferable over plasmapheresis in this population of GBS patients. It would also be crucial to follow these patients over time to identify the long-term disability as well as treatment outcomes.
更新日期：2021-01-01
京公网安备 11010802027423号